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ABSTRACT: Walnuts (Juglans regia L.), hazelnuts (Corylus avellana L.), and almonds (Prunus dulcis Mill.) are rich sources of
ellagitannins and proanthocyanidins. Gut microbiota plays a crucial role in modulating the bioavailability of these high molecular
weight polyphenols. However, to date there are no studies evaluating the capacity to produce nut phenolic metabolites in subjects
with metabolic syndrome (MetS), a pathology associated with an altered gut bacterial diversity. This study applied a LC-MS
targeted approach to analyze the urinary excretion of nut phenolic metabolites in MetS subjects following 12 weeks of nut
consumption, compared to sex- and age-matched individuals given a nut-free control diet. Metabolites were targeted in both
hydrolyzed and nonhydrolyzed urine by LC-PDA-QqQ-MS/MS analysis, and identification of metabolites lacking available
standards was confirmed by LC-ESI-ITD-FT-MS. Ellagitannin-derived urolithins A and B significantly increased after the nut-
enriched-diet, urolithins C and D were also detected, and a complex combination of urolithin-conjugated forms was observed in
nonhydrolyzed urine, confirming an extensive phase II metabolism after absorption. In contrast, no significant increases in
proanthocyanidin microbial metabolites were observed in urine following nut consumption. Because the intestinal microbiota of
the subjects in this study could catabolize ellagitannins into a wide range of urolithins, further research is strongly warranted on
the in vivo potential of these microbial metabolites in reducing cardiometabolic risk.
KEYWORDS: metabolic syndrome, nuts, polyphenols, microbiota, urolithins, hydroxyphenylvalerolactones
■ INTRODUCTION
Diet seems to play a pivotal role in the prevention, reversion,
and management of the metabolic syndrome (MetS), defined
as a constellation of co-occurring metabolic disturbances
including abdominal obesity, hyperglycemia, arterial hyper-
tension, and dyslipidemia, which determine an increased risk
for coronary artery disease, stroke, and type 2 diabetes.1 Tree
nuts have been recently proposed among the most promising
functional foods for managing both long- and short-term
cardiometabolic risk factors, especially walnuts (Juglans regia
L.), almonds (Prunus dulcis (Mill.) D.A. Webb), and hazelnuts
(Corylus avellana L.) traditionally associated with the
Mediterranean diet.2 Spain is particularly the southern
European country with the highest percentage of habitual nut
consumers and the greatest average portion sizes,3 and results
from the Spanish PREDIMED large clinical trial confirmed
that, when the Mediterranean diet is enriched with a moderate
intake of mixed nuts, a more incisive reduction in the
prevalence of the MetS is observed.4 The beneficial effects of
nuts already described range from the reduction of insulin
resistance and risk of type 2 diabetes5 to the improvement of
blood lipid profile,6 the reduction of adiposity,7 low-grade
systemic inflammation, and oxidative damage8 to the overall
protection from fatal and nonfatal cardiovascular disease
(CVD) outcomes.5,9 These health-promoting effects have
been traditionally explained as the sum of small positive
actions of nut macronutrients and micronutrients on the
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individual diagnostic components of the MetS.2 However,
nonnutritive phytochemicals contained in nuts, such as
phytosterols/phytostanols and polyphenols, seem to also
contribute to the protection against metabolic alterations.
Nut polyphenols are mainly located in the skin covering the
kernels and strongly vary depending on the nut species. Tannin
structures are the most abundant polyphenolic constituents,
with high molecular weight nonflavonoid hydrolyzable tannins
(ellagitannins, ETs) prevailing in walnuts,10 whereas flavonoid
condensed tannins (proanthocyanidins, PAs) represent the
major polyphenols described in almonds and hazelnuts.11
Although both in vitro and in vivo studies have recently
furnished new evidence on the anti-inflammatory, antiadipo-
genic, and antidiabetic potential of nut polyphenols,12−14 the
biological properties of these high molecular weight phyto-
chemicals are greatly dependent on their bioavailability. As a
common characteristic, ETs and PAs are not absorbed as such
and, once in the colon, they become fermentable substrates for
bacterial enzymes, leading to the extensive breakdown of their
original tannin structures into a number of smaller absorbable
metabolites.15 Within the large intestine, the ellagic acid (EA)
released from ET hydrolysis undergoes microbial enzymatic
transformation10,13,16,17 to produce a series of metabolites
called urolithins, characterized by a common 6H-dibenzo[b,d]-
pyran-6-one nucleus and a decreasing number of phenolic
hydroxyl groups (urolithin D → C → A → B).18 Also, aromatic
and phenolic structures including phenylvalerolactones and
phenylvaleric, phenylpropionic, phenylacetic, hippuric, and
benzoic acids, with different hydroxylation patterns, have
been already proposed as main products of the microbial
biotransformation of flavan-3-ol dimers, oligomers (DP > 3),
and PAs (flavan-3-ol polymers).19−22
The colonic bacteria responsible for ET and PA gut
transformation are only partly known,23 but do not seem to
be ubiquitous in the gut. In contrast, it is currently accepted
that obesity and MetS are associated with phylum-level changes
in the gut microbiota, reduced bacterial diversity, and altered
representation of bacterial genes and metabolic pathways,
including those involved in nutrient harvest.24 Despite the
potential contribution of bioactive metabolites bioavailable
from nut polyphenols in reducing cardiometabolic risk, to the
best of our knowledge no previous studies investigated the gut
microbial-derived metabolism of nut polyphenols in subjects
with diagnosed MetS or other metabolic disturbances
associated with an altered gut bacterial diversity.
A randomized parallel-group feeding trial was recently carried
out to evaluate the clinical effects on the MetS phenotype of a
12 week mixed-nut-enriched diet (30 g/day), compared to a
control diet.25−27 As previously published, a decreased insulin
resistance, a remarkably significant improvement in 8-oxo-7,8-
dihydro-20-deoxyguanosine urinary excretion, and a borderline
improvement in inflammatory markers was associated with the
MetS patients who consumed the mixed-nut supplement for 12
weeks, compared to those who abstained from nuts.25,26 In the
present study, we applied a liquid chromatography−mass
spectrometry (LC-MS) targeted approach to determine the
eventual concomitant changes in the urinary excretion of
microbial-derived phenolic metabolites of nut flavan-3-ols, PAs,
and ETs, following the nut intervention.
■ MATERIALS AND METHODS
Standards and Reagents. Urolithin A (3,8-dihydroxy-6H-
dibenzo[b,d]pyran-6-one, 95% purity), urolithin B (3-hydroxy-6H-
dibenzo[b,d]pyran-6-one, 98% purity), and urolithin B glucuronide
were synthesized according to the method of Lucas and co-workers,28
whereas urolithin A glucuronide was synthesized as previously
described.29 Phenylacetic acid, 3-hydroxyphenylacetic acid, 3,4-
dihydroxyphenylacetic (homoprotocatechuic) acid, 3-methoxy-4-hy-
droxyphenylacetic (homovanillic) acid, 3-hydroxyphenylpropionic
acid, 4-hydroxyphenylpropionic (phloretic) acid, 3,4-dihydroxyphenyl-
propionic (hydrocaffeic) acid, 3-(4-hydroxy-3-methoxyphenyl)-
propionic (hydroferulic) acid, 2-hydroxycinnamic (o-coumaric) acid,
4-hydroxycinnamic (p-coumaric) acid, 3,4-dihydroxycinnamic (caffeic)
acid, 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic (ferulic) acid, 3-(4-
hydroxy-3,5-dimethoxyphenyl)prop-2-enoic (sinapinic) acid, 2-hy-
droxybenzoic (salicylic) acid, 3- and 4-hydroxybenzoic acids, 2,5-
dihydroxybenzoic (gentisic) acid, 3,4-dihydroxybenzoic (protocate-
chuic) acid, 2,6-dihydroxybenzoic (γ-resorcylic) acid, 3,5-dihydrox-
ybenzoic (α-resorcylic) acid, 3,4,5-trihydroxybenzoic (gallic) acid, 4-O-
methylgallic acid, ellagic acid, (−)-epicatechin, (+)-catechin, ethyl
gallate, and β-glucuronidase/sulfatase from Helix pomatia were
purchased from Sigma-Aldrich (St. Louis, MO, USA). 4-Hydrox-
ybenzoylglycine (4-hydroxyhippuric) acid was purchased from
PhytoLab (GmbH & Co. KG). 4-Hydroxy-3-methoxybenzoic
(vanillic) acid, 3-hydroxycinnamic (m-coumaric) acid, and taxifolin
were purchased from Extrasynthes̀e (Genay, France). HPLC-grade
solvents methanol, acetonitrile, glacial acetic acid, and formic acid were
purchased from Chemie S.A. (Barcelona, Spain). Hydrochloric acid
was purchased from Panreac (Barcelona, Spain).
Subjects. Forty-one volunteers with diagnosed MetS (23 men and
18 women, ages between 31 and 63 years) participated in a
prospective, randomized, controlled, parallel-designed, 12 week
interventional feeding trial (see Supplemental Table 1 in the
Supporting Information). The design of the trial has been reported
in detail elsewhere.25,26 Briefly, subjects were screened from Primary
Care Centers affiliated with the Sant Joan University Hospital, Reus
(Spain), and recruited if meeting at least three of the updated criteria
for the diagnosis of MetS according to the National Cholesterol
Education Program’s Adult Treatment Panel III (ATP III):1 (1)
abdominal obesity, waist circumference ≥102 cm in men and ≥88 cm
in women; (2) hypertriglyceridemia, triglycerides ≥ 1.7 mmol/L or
drug treatment for elevated triglycerides; (3) low HDL cholesterol,
HDL cholesterol <0.9 mmol/L in men and <1.1 mmol/L in women,
or drug treatment; (4) hypertension, systolic blood pressure ≥130
mmHg and/or diastolic blood pressure ≥85 mmHg or antihyperten-
sive drug treatment; and (5) impaired fasting glucose, fasting blood
glucose ≥5.5 mmol/L. Exclusion criteria were a history of nut allergy;
established type 2 diabetes; body mass index (BMI) >35 kg/m2; acute
or chronic infection, inflammatory disease or endocrine disorders;
history of cancer; leukocytosis (>10 × 109 cells/L); anti-inflammatory,
corticosteroid, hormonal, or antibiotic drug treatment; a history of
alcohol abuse or drug dependence; and a restrictive diet or a weight
change ≥5 kg during the 3 months prior to the study. The protocol
was approved by the institutional review board, and all participants
provided written informed consent. This clinical trial was registered as
the International Standard Randomized Controlled Trial Number
(ISRCTN36468613).
Study Design. Subjects were stratified by sex and age (≤50 or >50
years) and subsequently randomly assigned to one of two 12 week
parallel intervention groups, the control (CT, n = 20) and the nuts
(NU, n = 22) groups. Participants of both groups were only advised to
follow the same qualitative dietary recommendations, according to the
American Heart Association dietary guidelines30 in the absence of any
low-in-polyphenols washout diet, to mimick their normal free-living
conditions as much as possible. The NU group also received a
supplement of 30 g/day of raw unpeeled mixed nuts (15 g of walnuts,
7.5 g of almonds, and 7.5 g of hazelnuts), whereas participants of the
CT group were advised against nut or peanut intake for the duration of
the study. Extra packages of nuts were distributed to the NU group
participants for family consumption, to increase compliance.
Participants were also instructed to maintain the same level of
physical activity throughout the study.
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Twenty-four hour urine samples were collected at baseline and at
the end of the 12 week intervention, starting in the morning after an
overnight fast. The 24 h total excreted volume of urine of each
volunteer was recorded, and aliquots were stored at −80 °C until
further analysis.
Dietary Information. Information on the food intake of the
subjects and on their adherence to the interventions was collected by 3
day food records at baseline and control visits, namely, every 4 weeks
during the trial. Recount of empty nut packages was an additional
criterion of adherence to the dietary intervention. The dietary intake of
flavonoids of the subjects was estimated by using the recently
expanded USDA databases,31 which are the most complete, updated,
and used databases in the estimation of flavonoid intake. Because
exhaustive and updated data on the ET content in food are still not
accessible, the total dietary intake of ellagic acid equivalents was
estimated by using the information available from the web-based
database Phenol-Explorer, version 1.5.2,32 as a measure of the intake of
both ellagic acid monomers (i.e., ellagic acid glycosides) and ETs.
Enzymatic Hydrolysis and Extraction of Phenolic Metabo-
lites from Urine Samples. Samples were subjected to enzymatic
hydrolysis through a previously validated methodology,33 to release
the aglycone phenolic metabolites from the conjugated forms and
easily identify and quantify the unconjugated forms through the help
of the available commercial standards. Briefly, the day of the analysis,
urine samples (500 μL) were thawed on ice in the dark, spiked with
100 μL of 2.02 nmol/L (400 ppb) ethyl gallate as internal standard,
and then vortexed, acidified with 25 μL of 0.58 mol/L acetic acid to
pH 4.9, and subsequently incubated with β-glucuronidase/sulfatase at
37 °C for 45 min. Immediately afterward, samples were acidified to pH
2 with 6 mol/L HCl, and the extraction of the unconjugated phenolic
metabolites was carried out using solid-phase extraction (SPE) Oasis
MCX 96-well plates (Waters) as previously described.33 The extracts
were reconstituted with 100 μL of initial mobile phase, vortexed for 5
min, and then transferred into a 96-well plate suitable for LC-MS/MS
analysis. For calibration purposes, an aqueous pool of commercially
available phenolic standards was serially diluted in synthetic urine
prepared as previously described34 and subjected to the extraction
procedure, as for the samples. Sample and standard preparation was
carried out in a dark room with a red safety light to avoid oxidation of
the analytes.
LC-PDA/ESI-QqQ-MS/MS Analysis of Phenolic Metabolites in
Hydrolyzed Urine. The analysis of phenolic metabolites in urine
samples was carried out by LC-PDA/ESI-MS/MS on an API 3000
triple-quadrupole mass spectrometer (ABSciex, Concord, ON,
Canada) equipped with a Turbo Ionspray source operating in negative
mode, coupled to an Acquity UPLC system equipped with a Waters
binary pump system (Milford, MA, USA) and a refrigerated
autosampler. UV spectral data were acquired in the range of 200−
400 nm. Separation was achieved on a Phenomenex Luna C18
analytical column (50 × 2.0 mm i.d., 5 μm) temperature controlled at
40 °C, at the chromatographic elution conditions previously described,
with some modifications.33 Turbo Ionspray source settings were as
follows: capillary voltage, −3700 V; nebulizer gas (N2), 10 (arbitrary
units); curtain gas (N2), 12 (arbitrary units); collision gas (N2), 5
(arbitrary units); entrance potential, −10 V; drying gas (N2), heated to
400 °C and introduced at a flow rate of 6000 cm3/min. The system
was controlled by software Analyst 1.4.2 supplied by ABSciex (Foster
City, CA, USA). Prior to analysis, direct infusion experiments were
carried out by infusing individual solutions of the standards available
(10 μg/mL) into the mass spectrometer using a model syringe pump
(Harvard Apparatus, Holliston, MA, USA), at a constant flow rate of 5
μL/min, and manual tuning was performed. For each standard
compound, the molecular ion [M − H]− in full scan mode and at least
the two most abundant fragment ions in product ion scan mode (m/z)
were detected. The optimal focusing potential (−200 → −80 V),
declustering potential (−70 → −20 V), and collision energy (−30 →
−10 V) for the fragmentation of the molecule ion were recorded. For
quantification, data were collected in the multiple-reaction monitoring
(MRM) mode, tracking the transition of the molecular to the main
product ion specific for each compound (Table 2), with a dwell time
of 40 ms. Metabolites lacking the commercial standards were
tentatively identified by matching the mass spectral data obtained by
targeted collision-induced fragmentation experiments (m/z 100−700)
with those previously reported,18,33 and the MRM transitions suitable
for quantification were recorded. Accuracy and precision met the
acceptance criteria.33
Phase II Conjugated Metabolites of Ellagic Acid and
Urolithins in Nonhydrolyzed Urine. In nonhydrolyzed urine,
phase II phenolic metabolites originated from ET microbial
metabolism (methyl and dimethyl ethers, glucuronic acid, and sulfate
esters or their combined forms) were then investigated in their actual
conjugated form by LC-PDA-MS/MS. The chromatographic, PDA,
and ESI operating conditions were the same as previously described,
with some modifications.18 A first screening profile of the possible
conjugated forms occurring in the samples was obtained by full-scan
data acquisition, followed by targeted collision-induced fragmentation
experiments (m/z 75−1000). Urolithins A and B and their
corresponding monoglucuronides were identified through the available
standards, and quantified through their corresponding calibration
curves, in the MRM mode (MRM transitions 403/227 and 387/211
for urolithin A glucuronide and urolithin B glucuronide, respectively).
The identification of ET and PA metabolites lacking the commercial
standards was tentatively achieved by matching the experimental UV
and MS/MS data with those previously reported in the literature.
When literature information on the metabolite MS spectral patterns
was poorly available, the compound's identity was confirmed by
multiple MS fragmentation experiments (see below). However, the
lack of suitable standards did not allow the quantification of these
conjugated metabolites.
LC-ESI-ITD-FT-MS. An LTQ Orbitrap Velos mass spectrometer
(Thermo Scientific, Hemel Hempstead, U.K.) equipped with an ESI
source was used for multiple MS fragmentation experiments, coupled
to an Accela system (Thermo Scientific) equipped with a quaternary
pump and a thermostated autosampler. The column and chromato-
graphic conditions were the same as employed in the LC-ESI-QqQ-
MS/MS targeted analysis. The ESI-FT-MS data were acquired in FT
MS mode (scan range from m/z 100−1000) and in MSn mode
(Orbitrap resolution range from 15000 to 30000 fwhm). Operation
parameters were as follows: source voltage, 4 kV; source current, 100
μA; S-Lens RF levels, 94%; sheath gas, 70 (arbitrary units); auxiliary
gas, 20 (arbitrary units); sweep gas, 0 (arbitrary units); and capillary
temperature, 325 °C. The instrument was calibrated with the Pierce
LTQ Velos ESI Positive Ion Calibration commercial solution to reach
the mass accuracy equipment specifications (RMS error < 2 ppm), and
then the tune method was optimized by direct infusion of a standard
solution of ellagic acid (5 ng/μL) at a constant flow rate of 5 μL/min
(ions at m/z 300.99898, 257.00915, 229.01424, and 185.02441). Mass
chromatograms and spectral data were acquired using XCalibur
software 2.0 (Thermo Scientific, San Jose, CA, USA).
Statistical Analysis. The concentration of the phenolic com-
pounds quantified in urine was expressed as μmol/24 h of urine
collection, and the eventual variation in their excretion following the
dietary intervention was reported as changes (Δ) between baseline
and 12 week urinary concentrations (Δ ± SEM). Statistical analyses
were carried out through SPSS 17.0 software (SPSS Inc., Chicago, IL,
USA). The nonparametric nature of the data was confirmed by the
Kolmogorov test, and then two distinct statistical tests were used to
jointly evaluate the effects of two factors. Within-group differences
between baseline and postintervention data were analyzed by the
Wilcoxon test for related samples (changes due to time factor),
whereas between-group differences (NU versus CT) were assessed by
the Kruskal−Wallis test for comparison between unpaired samples
(changes due to diet factor). To investigate the relationship between
the excretion of the total aglycone and monoglucuronide conjugated
forms of urolithins quantified in hydrolyzed and nonhydrolyzed urine,
respectively, correlation analysis (Spearman correlation coefficient)
were used. Differences were considered to be significant at p < 0.05.
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■ RESULTS AND DISCUSSION
Changes in the Dietary Intake of Flavonoids and
Ellagic Acid Equivalents. Adherence to the general dietary
recommendations was good, as evaluated from the 3 day food
records, as was compliance with nut ingestion in the NU group
(94%). At baseline, no between-group differences existed in the
daily intake of flavonoid and nonflavonoid polyphenolic
compounds (Table 1). In contrast, the nut-enriched diet
globally resulted in a significantly increased intake of EA
equivalents (p < 0.001) and PAs (p = 0.01) compared to the
control diet, consistent with the high content of ETs and PAs in
the mixed nuts administered (Table 1). The daily intake of PAs
was particularly the highest among all flavonoid subclasses,
already at baseline (98.8 and 125.0 mg/day in the NU and CT
groups, respectively, Table 1), in line with their ubiquitous
occurrence and intake in the human diet.35 The basal intake of
EA equivalents was relatively low in both groups, in agreement
with the limited occurrence of EA and ETs in edible plants and
their average intake in distinct populations.15
Gut Microbial Phenolic Metabolites of ETs in Hydro-
lyzed and Nonhydrolyzed Urine. Table 2 shows all of the
unconjugated phenolic metabolites targeted in hydrolyzed
urine, including potential gut microbial-derived phenolic
metabolites of ETs, flavan-3-ol oligomers, and PAs, as well as
flavan-3-ol monomers potentially excreted after the mixed-nut
consumption.
Three of the seven targeted ET-derived metabolites were
detected and quantified in hydrolyzed urine after the 12 week
nut consumption, namely, unconjugated EA and its main
microbial-derived dihydroxy- (urolithin A) and monohydroxy-
6H-dibenzo[b,d]pyran-6-one (urolithin B) metabolites. The
excretion of EA aglycone did not increase significantly in the
NU group at the end of the nut intervention (Table 2)
suggesting that, after the intraluminal hydrolysis of ETs, the
released EA is subjected to extensive microbial metabolism to
6H-dibenzo[b,d]pyran-6-one structures, as the preferential
catabolic route prior to absorption. According to the current
knowledge, the tri- and tetrahydroxylated 6H-dibenzo[b,d]-
pyran-6-one metabolites (urolithins C and D, respectively)
would be the first to be produced from the distal part of the
small intestine, where anaerobic bacteria responsible for the EA
metabolism seem to be already present. Their metabolism
would then continue along the colon, with the sequential
removal of hydroxyl groups, leading to the more lipophilic and
easily absorbed urolithins A and B.18,36 In line with previous
findings, the moderate daily consumption of nuts in our study
induced an increased excretion of walnut ET microbial-derived
urolithins. The concentration of urolithins A (MRM transition
227/198) and B (MRM transition 211/167) significantly
increased, in hydrolyzed urine, compared to the CT group
(Table 2), confirming them as the most representative
microbial metabolites of ETs.10,16,37 Unconjugated urolithins
C (MRM transition 243/199) and D (MRM transition 259/
215) were also detected (Figure 1), and their identification was
tentatively confirmed through LC-ESI-ITD-FTMS fragmenta-
tion experiments, although the lack of suitable commercial
standards did not allow their quantification. The early
production of urolithins C and D as products of ET
transformation was recently confirmed in vitro in the time
course profile of culture fermentation by human fecal
microbiota.36 In keeping with our results, the occurrence of
urolithin C and D conjugated metabolites was previously
detected in bile and plasma of Iberian pigs fed fresh acorns, and
traces of free urolithin C were also reported in urine, suggesting
that these less lipophilic urolithins may be also absorbed and
subjected to extensive enterohepatic circulation.18 The tentative
identification of urolithin D derivatives in human urine was not
reported previously.
In the present study, the targeted analysis of nonhydrolyzed
urine showed a complex combination of conjugated derivatives
of EA (EA glucuronide) and urolithins (Table 3). A total of
nine mono- (i.e., glucuronides), di- (i.e., sulfoglucuronides,
diglucuronides), and triconjugated forms of urolithins (i.e.,
traces of a methyl ether sulfoglucuronide conjugate of urolithin
C) predominated in urine after the nut intervention, although
free forms of urolithins A, B, and C were also detected. These
findings confirmed that, once absorbed, all of these low
molecular weight microbial-derived metabolites are further
subjected to first-pass phase II metabolism (glucuronidation,
methylation, sulfation, or combination of them) within the
enterocytes and/or hepatocytes, to finally enter the systemic
circulation, accumulate in tissues, or be eliminated in urine.18 In
general, conjugated forms with glucuronic acid predominated.
Thanks to the standards' availability, urolithin A and urolithin B
glucuronide derivatives were identified and quantified. The
Table 1. Estimated Intake (Milligrams per Day) of Flavonoids and Ellagic Acid Equivalents by the Daily Serving of Mixed Nuts,
through the Baseline Diet and as 12 Week Changes in the Two Interventionsa









(30 g) baseline dietb
change after






total flavonoids 15.32 40.24 9.46 65.02 188.21 ± 21.50 88.48 ± 6.01d 201.41 ± 25.97 −16.16 ± 6.64 0.01
flavan-3-ols equiv 0.36 0.42 0 0.78 21.38 ± 3.54 −1.92 ± 0.87 20.64 ± 2.89 −3.61 ± 1.21 0.61
proanthocyanidins
equiv
14.1 39.27 9.05 62.41 98.84 ± 15.03 77.80 ± 4.12d,e 125.04 ± 19.82 −16.16 ± 4.93 0.01
flavones equiv 0 0 0 0 3.20 ± 0.54 −0.37 ± 0.09 3.12 ± 0.75 −0.65 ± 0.18 0.98
flavonols equiv 0.63 0 0 0.63 23.37 ± 2.78 2.01 ± 0.57 21.75 ± 2.59 −2.56 ± 0.70 0.37
flavanones equiv 0.03 0.01 0 0.04 26.04 ± 6.82 6.66 ± 2.06 21.47 ± 6.14 3.10 ± 1.2 0.33
isoflavones equiv 0 0 0.01 0.01 1.03 ± 0.54 0.25 ± 0.14 0.42 ± 0.06 0.74 ± 0.15 0.29
anthocyanidins equiv 0.2 0.54 0.41 1.14 14.35 ± 2.19 4.54 ± 0.73 17.97 ± 3.87 9.19 ± 1.48 0.98
ellagic acid equiv 0 0 37.88 37.88 3.59 ± 1.54 32.70 ± 0.77d,e 7.51 ± 3.21 −4.35 ± 0.85 <0.001
aThe total daily intakes through the diet are expressed as the mean ± SEM. bNo significant between-group differences at baseline. cSignificance (p <
0.05) of the difference in changes between groups (nuts diet versus control diet), calculated by the unpaired Mann−Whitney U test. dSignificantly
different from baseline (p < 0.05) by paired samples test. ep < 0.001.
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main urolithin A monoglucuronide isomer represented the
most ubiquitously excreted urolithin following the 12 week
intervention (51.09 ± 9.41 μmol/24 h in the NU group),
accounting alone for the almost total urolithin A excretion
(Spearman coefficient = 0.845, p < 0.01) and suggesting an
eligible marker of ET-rich food intake not only in healthy10 but
also in MetS-diagnosed subjects. Also, the concentration of
urolithin B glucuronide (14.18 ± 6.44 μmol/24 h in the NU
group, following nut consumption) positively correlated with
the total excretion of urolithin B aglycone measured in
Table 2. Changes in the 24 h Urinary Excretion of Flavan-3-ol Monomers and Gut Microbial-Derived Phenolic Metabolites of
PAs and ETs following the 12 Week Intervention (NU versus CT) in Hydrolyzed Urinea
Δ ± SEM (μmol, 24 h)
phenolic metabolite MRM transition NU group CT group
ETs derivatives
ellagic acid 301/257 3.14 ± 2.98 0.24 ± 3.60
ellagic acid methyl ether 315/300 nd nd
ellagic acid dimethyl ether 329/300 nd nd
urolithin A 227/198 49.97 ± 1.93b,c −1.33 ± 0.97
urolithin B 211/167 23.20 ± 2.09b,c −2.74 ± 1.42
urolithin C 243/199 nq nq
urolithin D 259/215 nq nq
hydroxyphenyl-γ-valerolactones
5-(dihydroxyphenyl)-γ-valerolactone isomer 1 207/163 −31.60 ± 6.17 55.65 ± 7.62
5-(dihydroxyphenyl)-γ-valerolactone isomer 2 207/163 132.86 ± 30.46 60.81 ± 23.69
5-(trihydroxyphenyl)-γ-valerolactone 223/179 5.22 ± 1.59 −0.96 ± 0.25
hydroxyphenylpropionic acids
3-hydroxyphenylpropionic acid 165/121 2.03 ± 0.60 −4.40 ± 1.33
4-hydroxyphenylpropionic acid 165/121 0.28 ± 1.15 6.58 ± 1.34
3,4-dihydroxyphenylpropionic acid 181/137 0.68 ± 0.36 1.05 ± 0.49
3-(4-hydroxy-3-methoxyphenyl)propionic acid 195/136 −2.19 ± 1.80 2.14 ± 3.35
hydroxyphenylacetic acids
phenylacetic acid 135/91 2.28 ± 0.37 −0.25 ± 0.68
3-hydroxyphenylacetic acid 151/107 2.02 ± 0.75 3.54 ± 1.61
4-hydroxyphenylacetic acid 151/107 5.92 ± 5.98 6.92 ± 6.36
3,4-dihydroxyphenylacetic acid 167/123 9.20 ± 3.83 8.36 ± 4.98
3-methoxy-4-hydroxyphenylacetic acid 181/137 −10.39 ± 4.54 38.97 ± 8.02
hydroxycinnamic acids
o-coumaric acid 163/119 0.48 ± 0.15 0.33 ± 0.05
m-coumaric acid 163/119 −1.93 ± 0.57 1.55 ± 0.28
p-coumaric acid 163/119 −1.73 ± 0.55 0.93 ± 0.27
caffeic acid 179/135 3.78 ± 2.33 10.82 ± 1.17
ferulic acid 193/134 29.28 ± 13.25 27.64 ± 3.62
sinapinic acid 223/164 0.06 ± 0.06 0.69 ± 0.11
hydroxybenzoic acids
2-hydroxybenzoic acid 137/93 −1.80 ± 0.44 −1.45 ± 0.3
3-hydroxybenzoic acid 137/93 nd nd
4-hydroxybenzoic acid 137/93 5.13 ± 6.39 71.05 ± 15.1
2,5-dihydroxybenzoic acid 153/109 0.46 ± 0.34 −0.27 ± 0.32
2,6-dihydroxybenzoic acid 153/109 −4.22 ± 0.65 −0.010 ± 0.002
3,5-dihydroxybenzoic acid 153/109 −0.35 ± 0.78 −2.56 ± 1.08
protocatechuic acid 153/109 −0.93 ± 1.05 −3.09 ± 1.45
vanillic acid 167/152 −233.76 ± 39.14 119.98 ± 50.96
gallic acid 169/125 −0.85 ± 0.22 −0.09 ± 0.15
4-O-methylgallic acid 167/108 nd nd
hydroxyhippuric acids
3-hydroxyhippuric acid 194/150 4.69 ± 3.98 1.24 ± 4.77
4-hydroxyhippuric acid 194/100 2.09 ± 1.25 −19.33 ± 4.22
flavan-3-ols
(+)-catechin 289/245 0.11 ± 0.01 0.01 ± 0.04
(−)-epicatechin 289/245 nd nd
O-methylepicatechin 303/137 nd nd
(−)-epicatechin-3-O-gallate 441/289 nd nd
aData are the mean ± SEM. nd, not detected; nq, not quantified due to the lack of suitable standards. bSignificant difference from baseline (p < 0.05)
by paired samples test. cSignificance (p < 0.05) of the difference in changes between groups (NU group versus CT group), calculated by the
unpaired Mann−Whitney U test.
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hydrolyzed urine (Spearman coefficient = 0.834, p < 0.01),
although other undetected urolithin B conjugates probably
contributed to the total excretion of type B urolithins.
Finally, two urolithin A sulfoglucuronide isomers and a
urolithin C methyl ether sulfoglucuronide were the only sulfate
conjugates detected in this study, the latter mainly found in
traces. The urolithin A sulfoglucuronide isomers were
characterized by similar MS2 and MS3 daughter spectra (at
m/z 483 and 403, respectively) but distinct MS4 spectra at m/z
227 (Figure 2).
Interindividual Variability and Urolithin-Excreting
Capacity of MetS subjects. Interindividual differences in
the excretion rates of total urolithin A and B aglycones were
observed in hydrolyzed urine, as a typical characteristic of
microbial metabolism. Distinct combinations of phase II
conjugated forms of urolithins were also observed among
subjects after the nut intervention (Table 3). Nevertheless, the
lack of detection of urolithin A aglycone occurred in only two
subjects (∼9%) of the NU group following the nut intake,
unlike the strong interindividual variability previously observed
among healthy subjects ascribed to differences in their gut
microbiota.10,37 These findings demonstrated that, despite the
alterations in the gut microbiota recently associated with
obesity and MetS, the urolithin-producing and -excreting
capacity of the MetS-diagnosed subjects did not seem to be
compromised. Although interpersonal differences were ob-
served, in fact, the urinary excretion of urolithins A and B
clearly discriminated the subjects consuming nuts from those
abstaining and confirmed these compounds to be the most
characteristic microbial-derived metabolites of walnut ETs and
potentially eligible biomarkers of ET-rich food intake.
Interestingly, urolithin A and B aglycones were also detected
in some baseline or control urines after enzyme treatment (data
not shown), reflecting the punctual consumption of other
nonforbidden ET-rich foods (i.e., strawberries), as confirmed
by the 3 day food records.
The urolithin-excreting capacity in the subjects in the study
could be the consequence of a “urolithin prone-to-produce” gut
microbiota, potentially in accordance with the association of
obesity and related metabolic perturbations with a specific and
altered gut microbial community.24 However, it may also result
from a nut-induced gradual change in the colonic microflora of
the subjects in the study, along the 12 week intervention, in
keeping with the confirmed role of diet and, specifically, nut
polyphenols in modulating the colonic microbiota through
selective prebiotic effects.38−40 The lack of feces collection in
the present study did not allow verifying the fecal bacterial
composition of the subjects and the eventual nut-dependent
Figure 1. MRM trace chromatograms of (A) monohydroxy- (urolithin B), (B) dihydroxy- (urolithin A), (C) trihydroxy- (urolithin C), and (D)
tetrahydroxydibenzopyran-6-ones (urolithin D). (E) MS2 spectra of urolithin C by LC-ESI-ITD-FTMS.
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changes. For these reasons, further studies to identify the gut
bacterial strains responsible for the ET catabolism, to
investigate their relative occurrence in subjects with high
versus low cardiometabolic risk, and to compare the effects of
nut polyphenolic constituents in subjects with or without
metabolic disturbances, in the presence or absence of a
compromised microbial community, are strongly warranted. As
well, the prebiotic role of nut polyphenols in reverting
Bacteroides/Firmicutes balance and metabolic alterations
should be further investigated.14,36 These issues are relevant
to establish the bioefficacy of ETs in reducing cardiometabolic
risks if urolithins, besides being much more bioavailable than
the precursor compounds, could also been shown to have
higher in vivo bioactivities.12,37,41
Gut Microbial-Derived Phenolic Metabolites of PAs in
Hydrolyzed Urine. In hydrolyzed urine, 34 compounds
represented the targeted phenolic metabolites potentially
resulting from the complex microbial catabolism of flavan-3-ol
structures (dimers, oligomers, and PAs). Among them, 30
metabolites belonged to the classes of hydroxyphenylvaler-
olactones and hydroxyphenylpropionic, hydroxyphenylacetic,
hydroxycinnamic, hydroxybenzoic, and hydroxyhippuric acids
(Table 2) and are produced by sequential biotransformations
starting with the flavonoid C-ring-opening and followed by
lactonization, decarboxylation, dehydroxylation, and α- or β-
oxidation reactions.21,42 Four intact flavan-3-ol monomers were
also investigated in urine (Table 2) because their excretion may
result from the direct absorption of native monomeric flavan-3-
ols contained in almond and hazelnut skins,11,20 or from the
depolymerization of oligomeric and polymeric forms by the
interflavan cleavage, previously described as an alternative
microbial first step in the PA catabolic pathway.22
With the exception of 3-hydroxybenzoic acid and 4-O-
methylgallic acid, which were not detected, all of the targeted
hydroxyphenylvalerolactones and phenolic acids were already
excreted at baseline, in a wide range of concentrations. Among
the flavan-3-ol monomers, only (+)-catechin was detected and
quantified in hydrolyzed urine.
The excretion of hydroxyphenylvalerolactones was of
particular interest because, originating from the initial and
more specific reactions of flavonoid C-ring-opening followed by
lactonization, they are currently considered to be the most
eligible candidate biomarkers of flavan-3-ol intake;19,20 5-
(dihydroxyphenyl)-γ-valerolactones and 5-(trihydroxyphenyl)-
γ-valerolactones were specifically targeted, because of the
previous association with the microbial catabolism of (epi)-
catechin and (epi)gallocatechin moieties, respectively.19,43,44
Two mass signals were detected at the MRM transition 207/
163 (Figure 3A), indicating the possible occurrence of two
isomers of 5-(dihydroxyphenyl)-γ-valerolactone. The MS/MS
spectra of both metabolites were in line with that previously
proposed for 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone through
similar LC-ESI-QqQ-MS/MS analysis,33 and their LC-ESI-
ITD-FTMS fragmentation patterns (fragment ions at m/z
163.07575 and 122.03675) were tentatively confirmed to be in
the presence of two dihydroxyphenyl-γ-valerolactone isomers,
with the hydroxyl groups on distinct positions of the aromatic
ring. As well, a signal detected at the MRM transition 223/179
was assigned to 5-(trihydroxyphenyl)-γ-valerolactone (Figure
3B), and structural information obtained by MSn experiments
Figure 2. LC-ESI-ITD-FTMS spectra of the two urolithin A sulfoglucuronide isomers detected in nonhydrolyzed urine following the 12 weeks of nut
consumption: (A) MS2 daughter spectrum at m/z 483 shared by the two isomers; (B) MS3 daughter spectrum from the common fragment ion at m/
z 403; (C, D) distinct MS4 daughter spectra of the two urolithin A sulfoglucuronide isomers from the fragment ion at m/z 227.
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tentatively confirmed the compound identification (Figure
3C,D). However, although an apparent increased excretion of
dihydroxyphenyl-γ-valerolactone isomer 2 and trihydroxyphen-
yl-γ-valerolactone was observed in the NU group following nut
consumption (Table 2), all changes lacked statistical signifi-
cance, independent from the intervention group. In general, a
higher interindividual variation was observed in the excretion of
all the flavan-3-ol and PA potential phenolic metabolites, with
respect to urolithins.
Several factors probably played a role in compromising the
observation of significant changes in the urinary excretion of
phenolic derivatives of nut PAs. First, to mimick the normal
free-living conditions of the subjects in the study and not
perturb their gut microbial community, the study design lacked
a washout period based on a low-in-polyphenols diet, generally
used to reduce and standardize the baseline excretion of
phenolic metabolites. Consequently, the intake of PAs was
already high at baseline and, therefore, able to mask the
increased intake obtained through the moderate daily serving of
nuts (30 g). As well, besides the prohibition against eating nuts
or peanuts for the participants of the CT group, no other
flavonoid- or ET-rich foods were forbidden in both intervention
groups during the study, thus furnishing an uncontrolled
consumption of rich sources of all flavonoids subclasses and
particularly of PAs, which are ubiquitous in the human diet.
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(17) Gonzaĺez-Barrio, R. T. P.; Ito, H.; Espıń, J. C.; Tomaś-Barberań,
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Ellagitannins metabolites, urolithin-A-glucuronide and its aglycone
urolithin-A, ameliorate TNF-α induced inflammation and associated
molecular markers in human aortic endothelial cells. Mol. Nutr. Food
Res. 2012, DOI: 10.1002/mnfr.201100677.
(30) Krauss, R. M.; Eckel, R. H.; Howard, B.; Appel, L. J.; Daniels, S.
R.; Deckelbaum, R. J.; Erdman, J. W.; Kris-Etherton, P.; Goldberg, I. J.;
Kotchen, T. A.; Lichtenstein, A. H.; Mitch, W. E.; Mullis, R.;
Robinson, K.; Wylie-Rosett, J.; St. Jeor, S.; Suttie, J.; Tribble, D. L.;
Bazzarre, T. L. AHA Dietary Guidelines: Revision 2000: a statement
for healthcare professionals from the Nutrition Committee of the
American Heart Association. Circulation 2000, 102 (18), 2284−2299.
(31) Zamora-Ros, R.; Andres-Lacueva, C.; Lamuela-Raventoś, R. M.;
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C.; Chirlaque, M. D.; Tormo, M. J.; Quiroś, J. R.; Gonzaĺez, C. A.
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